Literature DB >> 24065117

Enhanced stem cell migration mediated by VCAM-1/VLA-4 interaction improves cardiac function in virus-induced dilated cardiomyopathy.

Stefan Brunner1, Hans D Theiss, Monika Leiss, Ulrich Grabmaier, Johanna Grabmeier, Bruno Huber, Markus Vallaster, Dirk Andre Clevert, Martina Sauter, Reinhard Kandolf, Christian Rimmbach, Robert David, Karin Klingel, Wolfgang-Michael Franz.   

Abstract

Endogenous circulation of bone marrow-derived cells (BMCs) was observed in patients with dilated cardiomyopathy (DCM) who showed cardiac upregulation of Vascular Cell Adhesion Protein-1 (VCAM-1). However, the underlying pathophysiology is currently unknown. Thus, we aimed to analyze circulation, migration and G-CSF-based mobilization of BMCs in a murine model of virus-induced DCM. Mice with coxsackievirus B3 (CVB3) induced DCM and healthy controls were analyzed regarding their myocardial homing factors by PCR. To determine cardiac VCAM-1 expression ELISA and immunohistochemistry were applied. Flow cytometry was performed to analyze BMCs. Cardiac diameters and function were evaluated by echocardiography before and 4 weeks after G-CSF treatment. In murine CVB3-induced DCM an increase of BMCs in peripheral blood and a decrease of BMCs in bone marrow was observed. We found an enhanced migration of Very Late Antigen-4 (VLA-4⁺) BMCs to the diseased heart overexpressing VCAM-1 and higher numbers of CD45CD34Sca-1⁺ and CD45CD34⁻c-kit⁺ cells. Mobilization of BMCs by G-CSF boosted migration along the VCAM-1/VLA-4 axis and reduced apoptosis of cardiomyocytes. Significant improvement of cardiac function was detected by echocardiography in G-CSF-treated mice. Blocking VCAM-1 by a neutralizing antibody reduced the G-CSF-dependent effects on stem cell migration and cardiac function. This is the first study showing that in virus-induced DCM VCAM-1/VLA-4 interaction is crucial for recruitment of circulating BMCs leading to beneficial anti-apoptotic effects resulting in improved cardiac function after G-CSF-induced mobilization.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24065117     DOI: 10.1007/s00395-013-0388-3

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  6 in total

Review 1.  Impact of parathyroid hormone on bone marrow-derived stem cell mobilization and migration.

Authors:  Bruno C Huber; Ulrich Grabmaier; Stefan Brunner
Journal:  World J Stem Cells       Date:  2014-11-26       Impact factor: 5.326

2.  Overexpression of VLA-4 in glial-restricted precursors enhances their endothelial docking and induces diapedesis in a mouse stroke model.

Authors:  Anna Jablonska; Daniel J Shea; Suyi Cao; Jeff Wm Bulte; Miroslaw Janowski; Konstantinos Konstantopoulos; Piotr Walczak
Journal:  J Cereb Blood Flow Metab       Date:  2017-04-24       Impact factor: 6.200

3.  Effects of diagnostic ultrasound-targeted microbubble destruction on the homing ability of bone marrow stromal cells to the kidney parenchyma.

Authors:  Gong Wang; Qian Zhang; Zhongxiong Zhuo; Shengzheng Wu; Zheng Liu; Hongmei Xia; Kaibin Tan; Linru Zou; Ling Gan; Yunhua Gao
Journal:  Eur Radiol       Date:  2015-12-04       Impact factor: 5.315

4.  Attenuation of cardiac hypertrophy by G-CSF is associated with enhanced migration of bone marrow-derived cells.

Authors:  Bruno C Huber; Nick L Beetz; Alexandra Laskowski; Tilman Ziegler; Ulrich Grabmaier; Christian Kupatt; Nadja Herbach; Ruediger Wanke; Wolfgang-Michael Franz; Steffen Massberg; Stefan Brunner
Journal:  J Cell Mol Med       Date:  2015-03-08       Impact factor: 5.310

5.  Anti-VCAM 1 Antibody-Coated Mesenchymal Stromal Cells Attenuate Experimental Colitis via Immunomodulation.

Authors:  Qianqian Chen; Yi Li; Zheng Chen; Haitao Du; Jun Wan
Journal:  Med Sci Monit       Date:  2019-06-15

6.  Soluble Vascular Cell Adhesion Molecule-1 (VCAM-1) as a Biomarker in the Mouse Model of Experimental Autoimmune Myocarditis (EAM).

Authors:  U Grabmaier; G Kania; J Kreiner; J Grabmeier; A Uhl; B C Huber; K Lackermair; N Herbach; A Todica; U Eriksson; L T Weckbach; S Brunner
Journal:  PLoS One       Date:  2016-08-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.